Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 6, 2006, Pages

  Greer, James J M ^a   Kakkar, Aman K ^b   Elrod, John W ^c   Watson, Lewis J ^d   Jones, Steven P ^d   Lefer, David J ^c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A; Echocardiography; Myocardial infarction; Nitric oxide; Ventricular remodeling

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; ENZYME INDUCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG EDEMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY DELAY;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE, CONGESTIVE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY EDEMA; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33845392012     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00347.2006     Document Type: Article

References (26)

1. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, and Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376, 2003.
2. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, and Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100: 292-298, 1999.
3. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985, 2001.
4. Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 99: 2972-2975, 1999.
5. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, and Zelis R. Endothelial function in chronic congestive heart failure. Am J Cardiol 69: 1596-1601, 1992.
6. Elrod JW and Lefer DJ. The effects of statins on endothelium, inflammation and cardioprotection. Drug News Perspect 18: 229-236, 2005.
7. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
8. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105: 868-873, 2002.
9. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, and Shimada K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 36: 325-329, 2000.
10. Jones SP, Gibson MF, Rimmer DM, 3rd Gibson TM, Sharp BR, and Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178, 2002.
11. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, and Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100: 4891-4896, 2003.
12. Jones SP, Trocha SD, and Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21: 2059-2064, 2001.
13. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
14. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, and Drexler H. Statininduced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939, 2004.
15. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, and Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102: 3104-3110, 2000.
16. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, and Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184, 1999.
17. Lefer AM, Scalia R, and Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 49: 281-287, 2001.
18. Libby P and Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 26: I11-14, 2003.
19. Libby P and Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 91: 4B-8B, 2003.
20. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, and Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104: 317-324, 2001.
21. Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT, Rouleau JR, Rouleau JL, Sussex BA, Theroux P, Vanden Belt RJ, and Braunwald E. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol recurrent events. J Am Coll Cardiol 33: 125-130, 1999.
22. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, and Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999.
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
24. Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB, Chao YS, and Bolognese JA. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest 69: 913-919, 1982.
25. Weis M, Heeschen C, Glassford AJ, and Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 105: 739-745, 2002.
26. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, and Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355, 2004.